Vaccine production: BioNTech has the right stuff
One of the vaccines that provides particularly good protection against Covid-19 is BNT162b2 from Mainz-based biotech company BioNTech. To scale-up the manufacturing capacity further, the company has begun production in Marburg – and relies on the expertise available at Siemens.
Make it real! Become a Digital Enterprise. We'll show you how at SPS 2022 from November 8th - 10th!
Technology innovations, best-in-class automation solutions, impressive exhibits and great networking opportunities are waiting for you! Meet us there and learn how to accelerate your digital transformation.
BioNTech manufactures BNT162b2 in collaboration with US pharmaceutical specialist Pfizer. The company has started manufacturing at the production site in Marburg, in the German state of Hesse. The plant there comes with an ultramodern production facility for recombinant proteins. The relevant expertise is also available, since BioNTech also acquired a highly qualified employee base along with the production facility, all of whom are experienced in developing new technologies.
The facility in Marburg had been producing influenza vaccines based on flu cell culture, then changed over to recombinant proteins for cancer treatments and now manufactures mRNA vaccine.
Full speed ahead thanks to total commitment
Now the hopes of society depend especially on this project. A project of this magnitude normally takes about a year, but in this case the participants completed the conversion in just five months. Main components of the new manufacturing execution system (MES) were completed in only two and a half months. “One factor that made it possible was the high level of cooperation between the teams and outstanding commitment by everyone involved,” states Andreas Haag, in charge of the project for Siemens.
In focus: Industry 4.0
All the improvements at the Marburg plant are Industry 4.0-compatible. One of the challenges with the conversion was the fact that it involved switching from rigid to mobile production with many single-use components. At the same time, working with mRNA meant a higher clean room class than was previously required in the facility. Paper is now an avoidable “contamination factor” that doesn’t arise with digital production. That was the basis for opting for the Opcenter Execution Pharma solution from Siemens as the new MES. This solution enables complete paperless manufacturing and fully electronic batch recording.
High degree of automation and digitalization
Seamlessly integrating automation solutions makes it possible to develop, optimize, and manage production processes automatically. Because mRNA processes include a lot of manual stages – weighing, for example – operators require guidance through these. This is provided by the workflow management component of the software. Opcenter Execution Pharma orchestrates the various sections of the system to ensure efficient production.
To automate the facility, all systems were converted to the latest version of Simatic PCS 7. The powerful, flexible, and scalable distributed control system steers and controls all the processes in the plant and takes digitalization to field level.
We want to thank Siemens for their excellent collaboration on this project and the huge effort they put in, often exceeding 100 percent.Valeska Schilling, Head of Production Department, BioNTech Marburg
Paperless production: more efficiency and quality
Paperless production offers advantages over traditional procedures in the pharmaceutical industry in particular. Electronic Master Batch Record Management enables users to create, execute, review, and release Master Batch Records (MBR), and Electronic Batch Records (eBR) are made faster. Testing is based on the principle of “review by exception” – in other words, deviations are dealt with when the system recognizes them based on exception rules. That makes the testing process less labor-intensive. As a result, digital production is a significant factor in making the process faster and improving quality.
Collaboration for a smooth start of production
To ensure a smooth start of production, Siemens is supporting the implementation of the system at BioNTech with Hypercare and a 24/7 project-based standby arrangement. The project is a complete success for both parties and production was able to start before the end of February with the production of the drug substance: the mRNA. “We want to thank Siemens for their excellent collaboration on this project and the huge effort they put in, often exceeding 100 percent,” says Valeska Schilling, Head of Production Department at BioNTech Marburg.
Both companies plan to intensify their collaboration for the rapid expansion and creation of production capacity for the Covid-19 vaccine. The aim is to establish new production sites for Covid-19 vaccine production worldwide based on the Marburg plant and its technology, starting with a production facility in Singapore. Within this cooperation, Siemens will provide the latest automation and digitalization technologies for BioNTech production sites, such as design, simulation, and engineering software as well as process control technology.
Pictures: © BioNTech SE 2021, all rights reserved
Subscribe to our Newsletter
Stay up to date at all times: everything you need to know about electrification, automation, and digitalization.